FinnCap Reaffirms Corporate Rating for Allergy Therapeutics (LON:AGY)
FinnCap reissued their corporate rating on shares of Allergy Therapeutics (LON:AGY) in a report published on Thursday, ThisIsMoney.Co.Uk reports.
Separately, Numis Securities reiterated a buy rating and set a GBX 35 ($0.46) target price on shares of Allergy Therapeutics in a research report on Monday, March 18th.
AGY opened at GBX 13.25 ($0.17) on Thursday. The company has a debt-to-equity ratio of 6.20, a quick ratio of 3.08 and a current ratio of 3.74. The company has a market capitalization of $84.29 million and a price-to-earnings ratio of -26.50. Allergy Therapeutics has a fifty-two week low of GBX 8 ($0.10) and a fifty-two week high of GBX 28.95 ($0.38). The firm’s 50-day moving average is GBX 13.69.
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.
Recommended Story: What is a conference call?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.